natgillin/translations-raw huggingface dataset:
- For the treatment of prostate cancer, docetaxel is administered in combination with prednisone or prednisolone. 
- Za liječenje karcinoma prostate docetaxel se primjenjuje u kombinaciji s prednizonom ili prednizolonom.
5 vials of 4 ml 
5 bočica od 4 ml
C-docetaxel has been conducted in three cancer patients. 
Provedeno je ispitivanje 14C-docetaksela na tri osobe s karcinomom.
In chemotherapy naïve patients treated for non-small cell lung cancer, the recommended dose regimen is docetaxel 75 mg/m² immediately followed by cisplatin 75 mg/m² over 30-60 minutes. 
Za bolesnike koji nisu prethodno primali kemoterapiju za karcinom nemalih stanica pluća preporučeni režim doziranja iznosi 75 mg/m2 docetaksela, nakon čega odmah slijedi infuzija 75 mg/m2 cisplatina u trajanju od 30 do 60 minuta.
In the adjuvant treatment of operable node-positive and node-negative breast cancer, the recommended dose of docetaxel is 75 mg/m² administered 1-hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² every 3 weeks for 6 cycles (TAC regimen) (see also Dose adjustments during treatment). 
Za adjuvantno liječenje operabilnog karcinoma dojke s pozitivnim i negativnim limfnim čvorovima, preporučena doza docetaksela od 75 mg/m2 primjenjuje se 1 sat nakon doksorubicina 50 mg/m2 i ciklofosfamida 500 mg/m2 svaka 3 tjedna tijekom 6 ciklusa (TAC protokol; vidjeti također 'Prilagodba doze tijekom liječenja').
Docetaxel was administered as a 1-hour infusion, all other medicinal products were given as intravenous bolus on day one. 
Docetaksel se primjenjivao u obliku jednosatne infuzije, a svi ostali lijekovi davali su se u intravenskom bolusu na dan 1.
Infusion site reaction; Pain 
Opći poremećaji i reakcije na mjestu primjene reakcije na mjestu primjene infuzije; bol
Data from one multicenter, randomised, controlled phase III clinical study support the use of docetaxel in combination with capecitabine for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline. 
Rezultati jedne multicentrične, randomizirane, kontrolirane, kliničke studije faze III podupiru primjenu docetaksela u kombinaciji s kapecitabinom za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom dojke nakon neuspješne citotoksične terapije koja je uključivala i antracikline.
What Docetaxel Mylan 200 mg/10 ml is and what it is used for What you need to know before you use Docetaxel Mylan 200 mg/10 ml How to use Docetaxel Mylan 200 mg/10 ml Possible side effects 
Što je Docetaxel Mylan 200 mg/10 ml i za što se koristi Što morate znati prije nego počnete primjenjivati Docetaxel Mylan 200 mg/10 ml Kako primjenjivati Docetaxel Mylan 200 mg/10 ml Moguće nuspojave
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 80 mg/4 ml 
SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 80 mg/4 ml
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/m² every three weeks, with trastuzumab administered weekly. 
U kombinaciji s trastuzumabom preporučena doza docetaksela iznosi 100 mg/m svaka tri tjedna, dok se trastuzumab primjenjuje svaki tjedan.
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20-115 mg/m² in phase I studies. 
Farmakokinetička svojstva docetaksela ispitivala su se u kliničkim ispitivanjima faze I u bolesnika s karcinomom nakon primjene 20 - 115 mg/m2.
• Docetaxel 75 mg/m² every 3 weeks for 10 cycles. 
• Docetaksel 75 mg/m2 svaka 3 tjedna tijekom 10 ciklusa.
- For the treatment of lung cancer, docetaxel could be administered either alone or in combination with cisplatin. 
- Za liječenje karcinoma pluća docetaxel se primjenjuje sam ili u kombinaciji s cisplatinom.
Docetaxel Mylan in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. 
Docetaxel Mylan u kombinaciji s cisplatinom i 5-fluorouracilom je indiciran za liječenje bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji nisu prethodno primali kemoterapiju za metastatsku bolest.
Arrhythmia (G3/4: 0.7%) Cardiac failure 
Srčani poremećaji aritmija (G3/4: 0,7%) zatajivanje srca
Unopened vial 12 months. 
12 mjeseci
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 20 mg/1 ml 
SADRŽAJ PO TEŽINI, VOLUMENU ILI DOZNOJ JEDINICI LIJEKA 20 mg/1 ml
In addition, physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2°C to 8°C. 
Nadalje, fizikalna i kemijska stabilnost infuzijske otopine u uporabi, pripremljene po propisu, dokazana je do 48 sati u ne-PVC vrećici pri temperaturi od 2°C do 8°C.
One vial of 4 ml of concentrate contains 1.58 g of ethanol anhydrous. 
Jedna bočica od 4 ml koncentrata sadržava 1,58 g etanola, bezvodnog.
95% CI p-value* 
95% CI p- vrijednost † *
Physical and chemical in-use stability of the infusion solution prepared as recommended has been demonstrated in non-PVC bags up to 48 hours when stored between 2°C to 8°C. 
Fizikalna i kemijska stabilnost infuzijske otopine u uporabi, pripremljene po propisu, dokazana je do 48 sati u ne-PVC vrećici pri temperaturi od 2 do 8ºC.
What Docetaxel Mylan 80 mg/4 ml is and what it is used for What you need to know before you use Docetaxel Mylan 80 mg/4 ml How to use Docetaxel Mylan 80 mg/4 ml Possible side effects 
Što je Docetaxel Mylan 80 mg/4 ml i za što se koristi Što morate znati prije nego počnete primjenjivati Docetaxel Mylan 80 mg/4 ml Kako primjenjivati Docetaxel Mylan 80 mg/4 ml Moguće nuspojave
Amenorrhoea was observed to be ongoing during follow-up in 121 patients out of the 202 patients with amenorrhoea at the end of the chemotherapy in study TAX316. 
U studiji TAX 316, od 202 bolesnice koje su imale amenoreju na kraju kemoterapije, amenoreja je i dalje bila prisutna u njih 121 tijekom praćenja nakon kemoterapije.
A multicenter, open-label, randomized study was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease. 
Provedena je multicentrična, randomizirana studija otvorenog tipa da bi se procijenila sigurnost i djelotvornost docetaksela u liječenju bolesnika s metastatskim adenokarcinomom želuca, uključujući adenokarcinom gastroezofagealnog spoja, koji prije toga nisu primali kemoterapiju za metastatsku bolest.
Each vial contains 1 ml of concentrate. 
Jedna bočica sadržava 1 ml koncentrata.
In combination with capecitabine, the recommended dose of docetaxel is 75 mg/m² every three weeks, combined with capecitabine at 1250 mg/m² twice daily (within 30 minutes after a meal) for 2 weeks followed by a 1-week rest period. 
U kombinaciji s kapecitabinom, preporučena doza docetaksela je 75 mg/m svaka tri tjedna u kombinaciji s kapecitabinom u dozi od 1250 mg/m2 dvaput dnevno (unutar pola sata nakon obroka) u trajanju od 2 tjedna, nakon čega slijedi tjedan dana pauze.
The concentrate is supplied in a clear colourless glass vial with a rubber stopper and a plastic flip-off cap. 
Pakiranje sadrži koncentrat u prozirnoj staklenoj bočici s gumenim čepom i plastičnim "flip-off" zatvaračem.
What Docetaxel Mylan 20 mg/1 ml is and what it is used for What you need to know before you use Docetaxel Mylan 20 mg/1 ml How to use Docetaxel Mylan 20 mg/1 ml Possible side effects 
Što je Docetaxel Mylan 20 mg/1 ml i za što se koristi Što morate znati prije nego počnete primjenjivati Docetaxel Mylan 20 mg/1 ml Kako primjenjivati Docetaxel Mylan 20 mg/1 ml Moguće nuspojave
QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate for solution for infusion contains 20 mg of docetaxel (anhydrous). 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna ml koncentrata za otopinu za infuziju sadržava 20 mg docetaksela (u obliku bezvodnog docetaksela).
1060 patients were randomized to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 
1060 bolesnika randomizirano je u skupine koje su primale ili docetaksela 75 mg/m2 primijenjen jedan sat nakon doksorubicina 50 mg/m2 i ciklofosfamida 500 mg/m2 (539 bolesnika u TAC skupini) ili doksorubicin 50 mg/m2 nakon kojeg slijedi fluorouracil
A total of 449 patients were randomized to receive either docetaxel monotherapy 100 mg/m² as a 1 hour infusion or paclitaxel 175 mg/m² as a 3 hour infusion. 
Ukupno 449 bolesnika dobivalo je ili docetaksel 100 mg/m2 u jednosatnoj infuziji kao monoterapiju ili paklitaksel 175 mg/m2 u trosatnoj infuziji.
- If you have any further questions, ask your doctor or hospital pharmacist. 
- Ako imate dodatnih pitanja, obratite se svom liječniku, bolničkom ljekarniku ili medicinskoj sestri.
Without primary G-CSF prophylaxis 
Bez primarne profilakse s
Each vial contains 4 ml of concentrate. 
Jedna bočica sadržava 4 ml koncentrata.
Infection associated with G4 neutropenia (G3/4: 4.6%) 
Infekcije i infestacije infekcije udružene s G4 neutropenijom (G3/4: 4,6%)
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m² as a 1 hour intravenous infusion every 3 weeks) and capecitabine (1250 mg/m² twice daily for 2 weeks followed by 1-week rest period). 
U ovoj studiji randomizirano je 255 bolesnika za liječenje docetakselom (75 mg/m2 u obliku jednosatne intravenske infuzije svaka 3 tjedna) i kapecitabinom (1250 mg/m dvaput dnevno tijekom 2 tjedna nakon čega slijedi jedan tjedan pauze).
• Docetaxel 30 mg/m² administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles. 
• Docetaksel 30 mg/m2 primijenjen tjedno prvih 5 tjedana u ciklusu liječenja od 6 tjedana,
DO NOT use other docetaxel medicinal products consisting of 2 vials (concentrate and solvent) with this medicinal product (Docetaxel Mylan concentrate for solution for infusion, which contains only 1 vial). 
Uz ovaj lijek (Docetaxel Mylan koncentrat za otopinu za infuziju) koji uključuje samo 1 bočicu NEMOJTE KORISTITI druge lijekove koji sadrže docetaksel i uključuju 2 bočice (koncentrat i otapalo).
The active substance is docetaxel. 
Djelatna tvar je docetaksel.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2).
Marketing Authorisation Holder and Manufacturer 
Nositelj odobrenja za stavljanje gotovog lijeka u promet i proizvođač:
Docetaxel Mylan in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. 
Docetaxel Mylan u kombinaciji s prednizonom ili prednizolonom indiciran je za liječenje bolesnika s metastatskim karcinomom prostate refraktornim na hormonsko liječenje.
After stratification according to the number of positive lymph nodes (1-3, 4+), 1491 patients were randomized to receive either docetaxel 75 mg/m² administered 1-hour after doxorubicin 50 mg/m² and cyclophosphamide 500 mg/m² (TAC arm), or doxorubicin 50 mg/m² followed by fluorouracil 500 mg/m² and cyclosphosphamide 500 mg/m² (FAC arm). 
Nakon stratifikacije prema broju pozitivnih limfnih čvorova (1-3, 4+), randomiziran je 1491 bolesnik u skupine koje će primati ili docetaksel 75 mg/m primijenjen jedan sat nakon doksorubicina 50 mg/m2 i ciklofosfamida 500 mg/m2 (TAC skupina) ili doksorubicin 50 mg/m2 nakon kojeg slijedi fluorouracil 500 mg/m2 i ciklofosfamid 500 mg (FAC skupina).
Each vial contains 10 ml of concentrate. 
Jedna bočica sadržava 10 ml koncentrata.
Inject the required volume of concentrate for solution into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion. 
Potrebni volumen koncentrata za otopinu za infuziju treba injicirati u infuzijsku vrećicu ili bocu od 250 ml koja sadrži ili 5%-tnu otopinu glukoze ili 0,9%-tnu (9 mg/ml) otopinu natrijevog klorida.
The recommended dose of docetaxel is 75 mg/m² as a 1-hour infusion, followed by cisplatin 75 mg/m², as a 1- to 3-hour infusion (both on day 1 only), followed by 5-fluorouracil 750 mg/m² per day given as a 24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion. 
Preporučena doza docetaksela je 75 mg/m2 u obliku jednosatne infuzije, nakon čega slijedi infuzija 75 mg/m cisplatine u trajanju od 1 do 3 sata (oboje samo na dan 1), a nakon završetka infuzije cisplatina slijedi kontinuirana 24-satna infuzija 5-fluorouracila 750 mg/m2 po danu u trajanju od 5
(G3/4: 0.6%); Nail disorders (G3/4: 0.4%) 
(G3/4: 0,6%) poremećaji noktiju (G3/4: 0,4%)
- For the treatment of metastatic gastric cancer, docetaxel is administered in combination with cisplatin and 5-fluorouracil. 
- Za liječenje uznapredovalog karcinoma želuca docetaxel se primjenjuje u kombinaciji s cisplatinom i 5-fluoruracilom.
At the median follow up time of 10 years and 5 months, TAC treated patients had a 16,5% reduction in the risk of relapse compared to those treated with FAC (hazard ratio = 0.84, 95% CI (0.65-1.08), p=0.1646). 
Pri medijanu vremena praćenja od 10 godina i 5 mjeseci u bolesnika liječenih u TAC skupini rizik povrata bolesti smanjio se za 16,5 % u odnosu na bolesnike liječene u FAC skupini (omjer hazarda =0 ,84, 95% CI (0,65-1,08), p=0,1646).
How to store Docetaxel Mylan 200 mg/10 ml Contents of the pack and other information 
Kako čuvati Docetaxel Mylan 200 mg/10 ml Sadržaj pakiranja i druge informacije
One vial of 10 ml of concentrate contains 200 mg of docetaxel. 
Jedna bočica s 10 ml koncentrata sadržava 200 mg docetaksela.
Use immediately the medicine once added into the non-PVC infusion bag. 
Nakon dodavanja lijeka u infuzijsku vrećicu koja nije izrađena od polivinilklorida (PVC), pripremljenu otopinu upotrijebite odmah.
This medicinal product contains 50 vol % ethanol (alcohol), i.e. up to 1.58 g per vial, equivalent to 40 ml of beer or 17 ml wine per vial. 
Ovaj lijek sadrži 50 vol% etanola (alkohol), odnosno do 1,58 g po bočici, što odgovara količini od 40 ml piva ili 17 ml vina po bočici.
One vial contains 200 mg of docetaxel. 
Jedna bočica sadržava 200 mg docetaksela.
How to store Docetaxel Mylan 80 mg/4 ml Contents of the pack and other information 
Kako čuvati Docetaxel Mylan 80 mg/4 ml Sadržaj pakiranja i druge informacije
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1 vial of 4 ml 
OBLIK I SADRŽAJ Koncentrat za otopinu za infuziju 1 bočica od 4 ml
What Docetaxel Mylan 20 mg/1 ml is and what it is used for 
Što je Docetaxel Mylan 20 mg/1 ml i za što se koristi
One vial of 10 ml of concentrate contains 3,95 g of ethanol anhydrous. 
Jedna bočica od 10 ml koncentrata sadržava 3,95 g etanola, bezvodnog.
More than one vial of concentrate for solution for infusion may be necessary to obtain the required dose for the patient. 
Ponekad je potrebno više od jedne bočice Docetaxel Mylan koncentrata za otopinu za infuziju kako bi se dobila doza potrebna za bolesnika.
Data from a multicenter open label randomized trial support the use of docetaxel for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy. 
Podaci iz multicentričnog, otvorenog, randomiziranog ispitivanja podupiru primjenu lijeka docetaksela za adjuvantno liječenje bolesnika s operabilnim karcinomom dojke i negativnim limfnim čvorovima, prikladnih za liječenje kemopterapijom.
What Docetaxel Mylan 80 mg/4 ml is and what it is used for 
Što je Docetaxel Mylan 80 mg/4 ml i za što se koristi
Hazard Ratio: 1.122 [97.2% CI: 0.937; 1.342]* Treatment difference: 5.4% [95% CI: -1.1; 12.0] 
Omjer hazarda: 1,122 [97,2% CI: 0,937; 1,342]*
What Docetaxel Mylan 200 mg/10 ml contains 
Što Docetaxel Mylan 200 mg/10 ml sadrži
How to store Docetaxel Mylan 20 mg/1 ml Contents of the pack and other information 
Kako čuvati Docetaxel Mylan 20 mg/1 ml Sadržaj pakiranja i druge informacije
• Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multicenter, open-label, randomized study (TAX323). 
• Indukcijska kemoterapija praćena radioterapijom (TAX 323) Sigurnost i djelotvornost docetaksela u indukcijskom liječenju bolesnika s karcinomom skvamoznih stanica glave i vrata (SCCHN) procjenjivala se u fazi III multicentrične, randomizirane studije otvorenog tipa (TAX323).
1060 patients were randomized to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m 
1060 bolesnika randomizirano je u skupine koje su primale ili docetaksela 75 mg/m2 primijenjen jedan sat nakon doksorubicina 50 mg/m2 i ciklofosfamida
• Induction chemotherapy followed by chemoradiotherapy (TAX324) The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomized, multicenter open-label, phase III study (TAX324). 
• Indukcijska kemoterapija nakon koje slijedi kemoradioterapija (TAX 324) Sigurnost i djelotvornost docetaksela u indukcijskom liječenju bolesnika s lokalno uznapredovalim karcinomom skvamoznih stanica glave i vrata (SCCHN) bili su evaluirani u randomiziranom, multicentričnom, otvorenom ispitivanju faze III (TAX324).
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² followed by cisplatin (P) 75 mg/m² followed by 5-fluorouracil (F) 750 mg/m² per day as a continuous infusion for 5 days. 
Bolesnici u docetaksel skupini primali su docetaksel (T) 75 mg/m nakon čega je slijedio cisplatin (P) 75 mg/m2 te 5-fluorouracil (F) 750 mg/m2 dnevno u obliku kontinuirane infuzije tijekom 5 dana.
Description of selected adverse reactions for adjuvant therapy with Docetaxel 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer 
Opis odabranih nuspojava za adjuvantno liječenje za docetakselom 75 mg/m u kombinaciji s doksorubicinom i ciklofosfamidom u bolesnika s karcinomom dojke s pozitivnim (TAX 316) i negativnim (GEICAM 9805) limfnim čvorovima
The infusion bag solution should be used within 6 hours below 25 °C and normal lighting conditions including the one hour infusion to the patient. 
Pripremljenu infuzijsku otopinu treba upotrijebiti unutar 6 sati nakon priprave, uključujući u to vrijeme i primjenu jednosatnom intravenskom infuzijom, uz čuvanje na temperaturi ispod 25°C te pri normalnoj svjetlosti.
After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm. No cases were reported in patients in FAC arm. No patient was diagnosed with myelodysplastic syndrome in either treatment groups. 
Nakon 10 godina praćenja u GEICAM 9805 studiji, akutna leukemija pojavila se u 1 od 532 bolesnika (0,2%) u TAC skupini.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1 vial of 1 ml 
OBLIK I SADRŽAJ Koncentrat za otopinu za infuziju 1 bočica od 1 ml
Menopausal status 
Menopauzalni status Premenopauza Postmenopauza
MARKETING AUTHORISATION NUMBER(S) EU/1/11/748/005 - 1 vial 
BROJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/11/748/005 - 1 vial
Patients on the comparator arm received cisplatin (P) 100 mg/m² as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 5. 
Bolesnici u usporednoj skupini primali su cisplatin (P) 100 mg/m kao 30-minutnu do trosatnu intravensku infuziju na dan 1, nakon čega je slijedila kontinuirana intravenska infuzija 5-fluorouracila (F) 1000 mg/m2 dnevno od dana 1 do dana 5.
One vial contains 80 mg of docetaxel. 
Jedna bočica sadržava 80 mg docetaksela.
What Docetaxel Mylan 20 mg/1 ml contains 
Što Docetaxel Mylan 20 mg/1 ml sadrži
If Docetaxel Mylan concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water. 
Ako Docetaxel Mylan koncentrat ili infuzijska otopina dođu u dodir s kožom, to mjesto odmah treba dobro i temeljito isprati sapunom i vodom.
In GEICAM 9805 study, alopecia persisted into the follow-up period (median follow-up time of 10 years and 5 months) and was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm. Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm. 
U GEICAM 9805 studiji, alopecija je i dalje bila prisutna tijekom perioda praćenja (medijan vremena praćenja od 10 godina i 5 mjeseci) i zabilježena je u 49 bolesnika (9,2%) u TAC skupini i u 35 bolesnika (6,7%) u FAC skupini.
How to store Docetaxel Mylan 200 mg/10 ml 
Kako čuvati Docetaxel Mylan 200 mg/10 ml
Each ml of concentrate for solution for infusion contains 20 mg docetaxel (anhydrous). 
Jedan ml koncentrata za otopinu za infuziju sadržava 20 mg docetaksela (bezvodnog).
Docetaxel Mylan in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease. 
Docetaxel Mylan u kombinaciji s trastuzumabom indiciran je za liječenje bolesnika s metastatskim karcinomom dojke i prekomjerno izraženim HER2, koji nisu ranije primali kemoterapiju za metastatsku bolest.
This medicine contains 50 vol % ethanol (alcohol), i.e. up to 0.395 g per vial equivalent to 10 ml of beer or 4 ml wine per vial. 
Ovaj lijek sadrži 50 vol% etanola (alkohol), odnosno do 0,395 g po bočici, što odgovara količini od 10 ml piva ili 4 ml vina po bočici.
Docetaxel Mylan is indicated for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer after failure of prior chemotherapy. 
Docetaxel Mylan je indiciran za liječenje bolesnika s lokalno uznapredovalim ili metastatskim karcinomom nemalih stanica pluća nakon neuspjeha prethodne kemoterapije.
Fatigue/weakness (G3/4: 5%); Oedema peripheral (G3/4: 1%) 
Opći poremećaji i reakcije na mjestu primjene umor/slabost (G3/4: 5%); periferni edem (G3/4: 1%)
This medicinal product contains 50 vol % ethanol (alcohol), i.e. up to 3.95 g per vial, equivalent to 100 ml of beer or 40 ml wine per vial. 
Ovaj lijek sadrži 50 vol% etanola (alkohol), odnosno do 3,95 g po bočici, što odgovara količini od 100 ml piva ili 40 ml vina po bočici.
6 ml clear glass Type I vial with a bromobutyl rubber stopper and aluminium seal and a plastic flip-off cap containing 1 ml of concentrate for solution for infusion. 
Prozirna staklena bočica od 6 ml (staklo tip I) s 1 ml koncentrata za otopinu za infuziju, s bromobutilnim gumenim čepom i aluminijskim prstenom te plastičnim "flip off" zatvaračem.
Patients on the comparator arm received cisplatin (P) 100 mg/m² followed by 5-fluorouracil (F) 1000 mg/m² per day for 5 days. 
Bolesnici u usporednoj skupini primali su cisplatin (P) 100 mg/m nakon čega je slijedio 5-fluorouracil (F) 1000 mg/m dnevno tijekom 5 dana.
Lacrimation increased (G3/4: <0.1%) 
Poremećaji oka pojačano suzenje (G3/4: <0,1%);
What Docetaxel Mylan 80 mg/4 ml contains 
Što Docetaxel Mylan 80 mg/4 ml sadrži
Infections and infestations Blood and lymphatic system disorders 
Infekcije i infestacije Poremećaji krvi i limfnog sustava neutropenija (G4:
Nausea (G3/4: 0.6%); Stomatitis (G3/4: 4.0%); 
Poremećaji probavnog sustava mučnina (G 3/4: 0,6%); stomatitis (G3/4: 4,0%);
Docetaxel Mylan 200 mg/10 ml concentrate for solution for infusion Docetaxel 
Docetaxel Mylan 200 mg/10 ml koncentrat za otopinu za infuziju docetaksel